October 8th 2024
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.
"Aquablation is versatile. It can manage a very wide range of prostate sizes and shapes," says Stephen Overholser, MD.
October 7th 2024
Illuccix is now indicated for use in the selection of patients with mCRPC for PSMA-targeted radionuclide therapy.
"Remember that whether or not it's your first time down the aisle, marriage is a celebration. Don't let all the financial and administrative details that go along with your special day spoil it," writes Jeff Witz, CFP.
Wayne G. Brisbane, MD, discusses AI-assisted HIFU for prostate cancer
"I think it's a really nice synergy between the 2 technologies," says Wayne G. Brisbane, MD.
Unlocking the potential of PSMA-PET: The need for interdisciplinary collaboration in image interpretation
"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR.
Study to compare TLX250-CDx vs contrast-enhanced CT for recurrent ccRCC
“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.
Ra223 plus SABR does not delay progression of oligometastatic HSPC
"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.
Device-related problems and event rates for PEG hydrogel spacers appear low
The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT
“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote.
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision.
PEG hydrogel spacer use shows growth in US men with prostate cancer
Overall, a total of 693 patients received a PEG spacer in 2017 and 2510 received one in 2022, an increase of 262%.
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS, explains how findings showing 5-year biochemical recurrence status may predict prostate cancer cure should alter the clinician-patient interaction.
Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC
At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.
Focal salvage HDR brachytherapy appears safe, efficacious in radiorecurrent prostate cancer
The 3-year biochemical progression-free survival was 61%, and the 3-year radiographic progression-free survival was 67%.
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Zaorsky discusses the patient safety misconceptions around radiotherapy for RCC, and considering patient-reported outcomes in future randomized controlled trials.
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
Findings from RAPTOR suggest 5-year biochemical recurrence may be a good indication of prostate cancer cure status.
BCR within 5 years is prognostic for metastasis, prostate cancer-specific mortality
The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did.
Nicolas Demogeot, MD: Impact of GETUG 14 on early-stage prostate cancer care
Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.
How do treatments for renal cell carcinoma differ in their effect on kidney function?
"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS.
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Zaorsky discusses his team's ASTRO 2024 abstract showing clear benefit of radiotherapy and ablation in reduced kidney effects in patients with RCC.
Pembrolizumab after TMT shows promise in muscle-invasive bladder cancer
“Pembrolizumab maintenance therapy after SABR boost to bladder tumor and concurrent radio-chemotherapy was well tolerated with promising efficacy in the early analysis," said Shang-bin Qin, MD.
PSMA-PET-guided intensification of salvage RT found safe, efficacious
“At a median follow-up of 37 months, we saw that failure-free survival was statistically significant, with 2 times more events seen in the control arm," said Colin Belliveau, MD.
Phase 3 trial progresses of padeliporfin VTP therapy in upper tract urothelial carcinoma
The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold.
Nicholas van As, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Van As makes the case for clinical evidence supporting the priority of SBRT, describing its convenience and cost-effectiveness without compromising outcomes.
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Blanchard provides an update on the SABRE trial, assessing an iodinated hydrogel space used for SBRT treatment in patients with prostate cancer.
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
Dandapani highlights her team's promising findings around combination Ra-223, SBRT and ADT therapy for metastatic castrate sensitive prostate cancer.
Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer
Findings from GETUG 14 show short-term ADT with high-dose radiotherapy provided 5-year improved efficacy without increased risk of toxicity.